Tumor Mutational Burden (TMB) is a predictive biomarker for response to immune checkpoint inhibitor therapy. Laboratories routinely measure TMB using a variety of NGS panels, employing different chemistries and informatics algorithms. Standardization of TMB scores by using a common set of reference standards allows for a more direct comparison of results and straightforward interpretation from tests performed in different labs and platforms.

Download our factsheet to learn more.